Respiratory syncytial virus infection
- PMID: 10485741
- DOI: 10.1016/S0140-6736(99)80040-3
Respiratory syncytial virus infection
Abstract
Respiratory syncytial virus (RSV), long recognised as the major viral pathogen of the lower respiratory tract of infants, has also been implicated in severe lung disease in adults, especially the elderly. This fact, and the demonstration that passive prophylaxis with either polyclonal or monoclonal antibody to RSV prevents severe lung disease in high-risk infants and children, has led to renewed interest in the immune mechanisms surrounding protection, and the development of vaccines
Similar articles
-
Prevention and treatment of respiratory syncytial virus infection in infants: an update.Expert Rev Vaccines. 2006 Apr;5(2):261-8. doi: 10.1586/14760584.5.2.261. Expert Rev Vaccines. 2006. PMID: 16608425 Review.
-
Antibodies for prevention and treatment of respiratory syncytial virus infections in children.Antivir Ther. 2012;17(1 Pt B):201-11. doi: 10.3851/IMP2061. Epub 2012 Feb 3. Antivir Ther. 2012. PMID: 22311607 Review.
-
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.Pediatrics. 2003 Dec;112(6 Pt 1):1442-6. Pediatrics. 2003. PMID: 14654627
-
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b. Pediatr Infect Dis J. 2012. PMID: 21960187
-
New strategies for control of respiratory syncytial virus infection.Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245. Curr Opin Infect Dis. 2008. PMID: 18978532 Review.
Cited by
-
Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias.Front Immunol. 2024 Apr 5;15:1382318. doi: 10.3389/fimmu.2024.1382318. eCollection 2024. Front Immunol. 2024. PMID: 38646538 Free PMC article.
-
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.J Infect Dis. 2024 Sep 23;230(3):e647-e656. doi: 10.1093/infdis/jiae081. J Infect Dis. 2024. PMID: 38385566 Free PMC article. Clinical Trial.
-
Direct long-acting antibodies: updating the language of RSV prevention to reflect the evolution of mAbs.J Prev Med Hyg. 2024 Jan 1;64(4):E377-E381. doi: 10.15167/2421-4248/jpmh2023.64.4.3070. eCollection 2023 Dec. J Prev Med Hyg. 2024. PMID: 38379744 Free PMC article.
-
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.BMC Infect Dis. 2024 Jan 18;24(1):99. doi: 10.1186/s12879-024-08988-9. BMC Infect Dis. 2024. PMID: 38238680 Free PMC article.
-
Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Adv Sci (Weinh). 2024 Mar;11(12):e2306729. doi: 10.1002/advs.202306729. Epub 2024 Jan 15. Adv Sci (Weinh). 2024. PMID: 38225749 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical